Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT07750951Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- May 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, IBI310 in rectal adenocarcinoma, sponsored by Xijing Hospital. Started May 2026; status: recruiting.
02
Drugs
sintilimabIBI310
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT07750951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07750951.